TCGA-FJ-A3Z7-01A-12R-A23N-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 31.04467806
- os_event
- false
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.420
- KRAS_SIGNALING_DN+0.390
- TNFA_SIGNALING_VIA_NFKB+0.350
- ANGIOGENESIS+0.290
- KRAS_SIGNALING_UP+0.280
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.250
- SPERMATOGENESIS+0.240
- INFLAMMATORY_RESPONSE+0.230
- COAGULATION+0.200
- MYOGENESIS+0.190
Top 10 suppressed
- MYC_TARGETS_V1-0.680
- OXIDATIVE_PHOSPHORYLATION-0.600
- DNA_REPAIR-0.570
- E2F_TARGETS-0.570
- G2M_CHECKPOINT-0.570
- MYC_TARGETS_V2-0.560
- MITOTIC_SPINDLE-0.520
- PROTEIN_SECRETION-0.510
- PI3K_AKT_MTOR_SIGNALING-0.490
- UNFOLDED_PROTEIN_RESPONSE-0.480
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-1142 | Med | Medulloblastoma | 0.951 |
| 2 | MNG466 | — | — | 0.946 |
| 3 | SRR12202435 | — | — | 0.938 |
| 4 | SJEPD001523_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.936 |
| 5 | MNG1135 | — | — | 0.936 |
| 6 | MNG204 | — | — | 0.936 |
| 7 | MNG436 | — | — | 0.929 |
| 8 | SRR1459423 | GTEX | — | 0.927 |
| 9 | SRR1340301 | GTEX | — | 0.927 |
| 10 | SRR1334440 | GTEX | — | 0.926 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.420 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.390 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.350 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.290 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.280 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.250 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.240 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.230 | Idelalisib | — uncovered |
| COAGULATION | 0.200 | Binimetinib | — uncovered |
| MYOGENESIS | 0.190 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.090 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.070 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.010 | Idelalisib | — uncovered |